Piramal Pharma Ii Profile
Key Indicators
- Authorised Capital ₹ 50.00 Cr
- Paid Up Capital ₹ 34.01 Cr
- Company Age 2 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
About Piramal Pharma Ii
Piramal Pharma Ii Private Limited (PPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 June 2022 (Two years and eight months 14 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 50.00 Cr and a paid-up capital of Rs 34.01 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Piramal Pharma Ii Private Limited India are Akshita Jain as COMPANY SECRETARY and Amit Bapat as Cfo. Surinder Gulati and Amit Bapat serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230MH2022PTC384232
- Company No.
384232
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jun 2022
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Piramal Pharma Ii?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Akshita Jain | Company Secretary | 06-Mar-2023 | Current |
| Amit Bapat | CFO | 30-May-2023 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surinder Gulati  | Director | 08-Jun-2022 | Current |
Financial Performance of Piramal Pharma Ii.
Enhance accessibility to Piramal Pharma Ii's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Piramal Pharma Ii?
Unlock access to Piramal Pharma Ii's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Piramal Pharma Ii?
Piramal Pharma Ii has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Piramal Pharma Ii, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Piramal Pharma Ii's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
